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ABSTRACT
Few clinical studies have investigated the value of phosphate (P)-lowering therapies in early chronic kidney disease (CKD)
patients in whom hyperphosphataemia has not yet clearly developed and they report conflicting and even unexpected
results. In this issue of Clinical Kidney Journal, de Krijger et al. found that sevelamer carbonate (4.8 g/day for 8 weeks) did not
induce a significant reduction of pulse wave velocity (PWV) and that fibroblast growth factor 23 (FGF23) did not decrease
despite a decline in 24-h urine P excretion. To some extent these findings challenge the concept that ‘preventive’ P binder
therapy to lower FGF23 is a useful approach, at least over this short period of time. Interestingly, in a subgroup of patients
with absent or limited abdominal vascular calcification, treatment did result in a statistically significant reduction in
adjusted PWV, suggesting that PWV is amenable to improvement in this subset. Interpretation of the scarce and
heterogeneous observations described in early CKD remains difficult and causality and/or the possibility of ‘preventive’
treatment may not yet be completely disregarded. Moreover, de Krijger et al. contribute to the identification of new sources
of bias and methodological issues that may lead to more personalized treatments, always bearing in mind that not all
patients and not all P binders are equal.
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Chronic kidney disease (CKD) in general and the associated
mineral and bone disorders (MBDs) in particular have both been
related to markedly increased morbidity and mortality [1, 2]. In
the context of CKD-MBD, phosphate (P) and fibroblast growth
factor 23 (FGF23) are considered independent cardiovascular
risk factors [3, 4]. In fact, P and FGF23 have been closely associ-
ated with left ventricular hypertrophy, vascular calcification
(VC) and mortality, among other deleterious effects [5–7]. Many
studies, most of them performed in ‘dialysis’ patients, have
clearly shown that P levels (high and low) and P binder treat-
ment [8–10], high FGF23 concentrations (in both dialysis and
CKD patients) [3, 4] and longitudinally increaing FGF23 trajecto-
ries [11] are associated with CKD progression, cardiovascular
morbidity and/or mortality. Moreover, a number of experimen-
tal and observational studies, meta-analyses and randomized
clinical trials (RCTs) have shown that calcium (Ca)-free-P
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binders (mainly sevelamer in dialysis patients) attenuate the
progression of VC as compared with Ca-based P binders [12–15].
Ca-free P binders may also decrease the number of hospitaliza-
tions and improve survival, at least in some studies and sub-
groups of dialysis patients (i.e. those 65 years of age) [15–21].
However, these seemingly very positive results are still a matter
of debate and controversy [18, 21], at least partly due to their im-
portant financial implications. Thus it is still considered not
definitely proven that P-lowering treatment (by means of differ-
ent P binders) clearly improves hard outcomes [18, 21]. In any
case, lowering elevated P levels towards the normal range was
suggested by the recent 2017 Kidney Disease: Improving Global
Outcomes (KDIGO) guidelines for patients with CKD Stages 3a–
5d [Guideline 4.1.2; evidence 2C] [22]. These guidelines also
stated that decisions about P-lowering treatment (diet, dialysis
and P binders) should be based on progressively or persistently
elevated serum P (Guideline 4.1.5; not graded). In addition, it
was suggested that the dose of Ca-based P binders should be re-
stricted in adult patients (Guideline 4.1.6; the evidence grade
was upgraded to 2B) [22, 23].
In contrast, new pathophysiological insights into P homoeo-
stasis and the roles of FGF23 and Klotho in early CKD have led to
the performance of clinical studies to investigate the value of P-
lowering therapies in CKD patients in whom hyperphosphatae-
mia has not yet clearly developed [13, 24, 25]. Several reports
have shown that not only dietary P restriction but also sevelamer
and, in general, Ca-free P binders may decrease FGF23 levels [13,
26–28]. However, it is unknown whether lowering FGF23 improves
hard outcomes and therefore whether targeting FGF23 could be a
useful strategy. Consequently, the 2017 KDIGO guidelines empha-
size the perception that early ‘preventive’ P-lowering treatment
(i.e. in patients with early P retention represented by increased in-
tact or C-terminal FGF23 levels without hyperphosphataemia) is
currently not supported by data [22]. Although it is recognized
that preventing, rather than treating, hyperphosphataemia may
be of value in patients with CKD Stages 3a–5d, it is acknowledged
that current data are inadequate to support either the safety or
the efficacy of such a ‘preventive’ approach, encouraging re-
search in this specific area [22].
Two important RCTs addressing hard endpoints were evalu-
ated by the 2017 KDIGO review team in non-dialysis CKD
patients, leading to the suggestions mentioned above. Di Iorio et
al. [13], in a multicentre non-blinded pilot study, randomized
212 consecutive outpatients (CKD Stages 3–4) to receive either
sevelamer or Ca carbonate without a placebo control. The P con-
centration was maintained at between 2.7 and 4.6 mg/dL (nor-
mal values) for patients with CKD Stages 3–4 and between 3.5
and 5.5 mg/dL for those patients reaching CKD Stage 5. In addi-
tion to the coronary artery calcification (CAC) score, assessed at
study entry for up to 24 months, all-cause mortality and dialysis
inception were recorded for up to 36 months. FGF23 was not
measured. The authors found that sevelamer provided benefits
with respect to all-cause mortality and in the composite end-
point of death and dialysis inception, but not dialysis inception
alone. It could not be definitely proven whether these findings
demonstrate that compared with Ca-based agents, Ca-free P
binders offer either a potential for benefit or an absence of
harm. In this context, it should be pointed out that many exper-
imental and clinical studies have shown a vast array of pleiotro-
pic effects of sevelamer beyond P and/or FGF23 control [28–30].
Most of these actions could theoretically have contributed to
the positive impacts on VC and survival attributed to sevelamer
not only in dialysis but also in non-dialysis patients [13, 14, 16,
19].
In the second RCT evaluated by the 2017 KDIGO review
team, Block et al. [25] analysed 148 non-dialysis CKD patients
(Stages 3b–4) with normal or near-normal P levels [mean base-
line serum P concentration 4.2 mg/dL (1.36 mmol/L)]. Patients
were randomly assigned to receive one of three different P bind-
ers (sevelamer carbonate, lanthanum carbonate or Ca acetate)
or matching placebo. While there was a small decrease in serum
P concentrations in those allocated to active P binder treatment
and a 22% decrease in urinary P excretion, no significant differ-
ence was observed in the change in C-terminal FGF23 levels be-
tween patients who received P binders versus placebo.
Moreover, in contrast to the authors’ expectations, progression
of CAC and aortic VC was found in the ‘active’ treatment group,
whereas there was no progression in the placebo arm. Subgroup
analysis suggested that this negative unexpected effect was
accounted for by Ca acetate treatment. This explanation was
further supported by a metabolic study [31] in a small group of
eight patients with CKD Stages 3–4 in whom the addition of
1500 mg/day of Ca carbonate (3 weeks) caused a significantly
positive Ca balance, as measured by Ca kinetics, without affect-
ing baseline neutral P balance and with only a modest reduction
in urine P excretion. This kinetic study demonstrated a positive
net bone balance that was lower than the overall Ca balance,
thus suggesting soft tissue deposition. This study also sup-
ported results reported previously by Spiegel and Brady [32] in
six normophosphataemic adults with CKD Stages 3b–4 versus
six normal control subjects in which potential harms of liberal
Ca exposure in such cohorts was suggested (with total intakes
as low as 800 and 1000 mg/day, respectively). However, due to
the small number of patients and short duration, these studies
were not considered to fulfil the predefined inclusion criteria
for 2017 KDIGO full evidence review [22]. Moreover, the evidence
grade was not higher because none of the studies provided suf-
ficient dose threshold information about Ca exposure or infor-
mation on the safety of moderately dosed Ca-based P binders
[22]. Importantly, the Block et al. study [25] did not show a supe-
riority of Ca-free P binders versus placebo in terms of progres-
sion of the CAC surrogate endpoint, calling into question the
efficacy and safety of P binding in this particular population
[22]. Nevertheless, it is worth considering that this study was
exploratory and underpowered to detect differences between P
binders.
In view of these considerations, the 2017 KDIGO guidelines
state that in addition to the need to conduct Ca and P balance
studies across all CKD stages, prospective RCTs should be un-
dertaken to investigate the value of FGF23 levels (and possibly
Klotho) as an indicator for establishing P-lowering therapies
[22]. This is obviously especially relevant for non-dialysis CKD
patients. More importantly, RCTs regarding patient-centred out-
comes, major adverse cardiovascular events and/or survival
endpoints seem urgently needed. In addition, the guidelines
mention that the analysis of other endpoints such as CKD pro-
gression or cardiovascular calcifications would be desirable [22],
although the latter is viewed as a hard but surrogate endpoint.
Following from this line of promising studies, in this issue of
Clinical Kidney Journal, de Krijger et al. [33] report on an interest-
ing evaluation of whether sevelamer carbonate induces an im-
provement in carotid femoral PWV (as the primary outcome)
and whether this effect is mediated by a decline in FGF23. It is
well known that PWV is a measure of arterial stiffness and a
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surrogate marker for cardiovascular calcification, cardiovascu-
lar events and all-cause mortality, including in patients with
CKD [34].
Sevelamer was the first polymer developed as a P binder for
patients with CKD, and there is now >20 years of clinical experi-
ence in its use within the context of a multiple therapeutic ap-
proach to CKD-MBD (including vitamin D, calcimimetics and/or
Ca supplements) [35, 36]. Sevelamer carbonate (instead of hy-
drochloride) was subsequently developed mainly because
patients with CKD are already predisposed to developing meta-
bolic acidosis. Sevelamer carbonate received approval for use
not only in dialysis patients but also in adult non-dialysis CKD
patients with P levels 1.78 mmol/L (5.5 mg/dL). It has also been
recently approved for the control of hyperphosphataemia in
paediatric patients (6 years of age and with a body surface area
0.75 m2) [37].
The above-mentioned study by de Krijger et al. [33] is a pro-
spective, single-centre, single-arm pilot analysis in 24 normo-
phosphataemic CKD Stage 3 patients [mean estimated
glomerular filtration rate (eGFR) 43610 mL/min/1.73 m2]. The
authors found that treatment with a high fixed dose (2.4 g twice
daily) of sevelamer carbonate over 8 weeks did not induce a sig-
nificant reduction in PWV [9.26 2.3 versus 8.762.4 m/s
(P¼ 0.12); PWV values <8 m/s were defined as normal] in the 18
patients who completed the study. Moreover, FGF23 did not de-
crease during treatment, although a decline in 24-h urinary P
excretion was observed. Also, serum P concentration did not
change during this period (after excluding, per protocol, three
patients who developed hypophosphataemia after 1 week of
treatment). Therefore, to some extent, these results do not sup-
port the assumption of beneficial effects of early treatment of P
exposure to improve cardiovascular risks in all CKD patients, at
least as evaluated by PWV.
Nevertheless, it is very interesting that the authors report
that in a subgroup of patients with absent or limited abdominal
VC (lower Kauppila score), treatment resulted in a statistically
significant reduction in PWV after the necessary adjustment for
mean arterial pressure. This potential benefit in terms of PWV
improvement in a subset of patients could not be reliably attrib-
uted to a change in FGF23, rather it seemed more likely to have
been induced by lower P exposure (represented by a lower uri-
nary excretion of P). The effect of sevelamer on PWV appeared
to be independent of FGF23 after elegant statistical analysis.
Thus the subgroup results suggest that PWV is at least amena-
ble to improvement by ‘preventive’ treatment over this short
period of time, at least in CKD patients with a low calcification
score. Short-term modifications of PWV and of the augmenta-
tion index (as a measure of arterial wave reflections) have been
described with L-arginine or statins in several non-CKD studies
within 2–3 days or 8 weeks, respectively [38, 39]. In CKD (Stages
2–4) patients, L-arginine resulted in a significant improvement
of both carotid–femoral PWV (13.066 2.65 versus 10.6261.93 m/s)
and augmentation index after 12 weeks of follow-up [40].
It is known that PWV may be greatly increased even in the
early stages of CKD [34]. Many possible reasons have been put
forward to explain progressive stiffness as eGFR declines, in-
cluding endothelial dysfunction, subclinical atherosclerosis, VC
and CKD-MBD-related factors, among many others [34]. All
these factors may already be present in non-dialysis CKD and
they have also been associated with P and/or FGF23 through
mechanisms not completely elucidated. In fact, severe VC
(a factor that contributes to arterial stiffness but is unlikely to
be modifiable with such a short-term intervention) is already
frequently present in non-dialysis CKD, as described by us and
many others [41, 42]. Of utmost interest is the recognition by de
Krijger et al. [33] that the degree of VC will have to be taken
into account when analysing these potential quick vascular
responses to treatments. In incident peritoneal dialysis
patients, it was previously shown that PWV can change in ei-
ther direction at >6 months and that changes are associated
with modifiable risk factors such as the use of Ca-based P bind-
ers [43]. In hyperphosphataemic haemodialysis patients, other
authors have reported that treatment with sevelamer attenu-
ated within 6 months the progressive increase in PWV observed
during Ca carbonate treatment [44]. Sevelamer >11 months was
also associated with an improvement in aortic stiffness without
affecting the serum levels of several inhibitors of VC [45].
Neither measurements of FGF23 nor VC were evaluated in these
studies.
In a different CKD setting, no effect of sevelamer on PWV or
on intact FGF23 was found in a 10-month study in which 109
normophosphataemic patients with CKD Stage 3 were random-
ized to sevelamer or placebo [46], perhaps because PWV results
were not corrected for blood pressure (a PWV key determinant).
While a subgroup analysis of highly compliant subjects revealed
significant decreases in FGF23 and urinary P concentration in
patients receiving sevelamer (versus placebo), no difference in
serum P or Klotho was observed.
Interpretation of all these scarce and heterogeneous obser-
vations remains difficult. Different CKD stages, lack of stan-
dardization of P and Ca intake, different doses and type of P
binders and/or vitamin D compounds, the presence of controls,
measurement of different FGF23 molecules, different basal labo-
ratory or PWV values, unidentical adjustments of PWV parame-
ters or arterial pressure control, diverse case mixes and
differences in statistical power analysis may all have contrib-
uted to the observed wide scattering of results. It is also impor-
tant to note that the reported decline in eGFR may also justify
the lack of beneficial effect of sevelamer on FGF23 levels, blur-
ring potential expected effects of treatment. FGF23 did not de-
crease despite potentially declining calcitriol levels (due to renal
function impairment and/or sevelamer interference with ab-
sorption of liposoluble vitamins). In fact, after correcting for
eGFR/calcitriol, a statistically significant decline in FGF23 con-
centration was found following treatment [33]. More impor-
tantly, the authors [33] noted that the degree of VC has to be
taken into account when trying to investigate early vascular
changes or responses to treatments in this population. In other
words, future studies aimed at improving cardiovascular risk by
modifying early surrogate markers such as PWV should proba-
bly be focused on patients with limited VC. In contrast, although
FGF23 (secondary outcome and linked to both P and Ca homoeo-
stasis) is reported to be closely associated with microvascular
function in CKD [47, 48], in this real-life and other studies,
changes in FGF23 did not seem directly related to PWV [33, 46].
However, causality and/or the possibility of preventive treat-
ment of deleterious hyperphosphataemia in CKD patients may
not yet be completely ruled out, since low discriminatory power
may hinder the potential impact of any manoeuvre or mecha-
nistic pathway analysis.
In summary, de Krijger et al. [33] provide nice original infor-
mation that contributes to an area in which nephrologists are in
need of new information, clearer identification of sources of
bias and identification of methodological issues that may
lead to more personalized treatments, always bearing in mind
that not all patients and not all P binders are equal [49]. In the
meantime, we await clear-cut prospective RCTs in normo-
phoshataemic patients that analyse really hard outcomes. This
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is definitely one of the major gaps in knowledge that we cur-
rently face in the management of early CKD-MBD [49]. However,
as recently shown in the CKD Optimal Management With
BInders and NicotinamidE trial, reducing P and FGF23 in non-
dialysis CKD may require completely new approaches [50] and,
as stated in the current guidelines [22], potential P loading with
normophosphataemia may not be an indication to start P bind-
ers. Whether disproportional elevations in serum FGF23 con-
centrations may become a signal to start P-lowering therapies
or a future target with other drugs in early CKD will also need to
be investigated.
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